October 02, 2024

Global Brain has invested in GC Therapeutics, Inc. to drive next-generation iPSC cell therapies

Global Brain has invested in GC Therapeutics, Inc. (GCTx), a groundbreaking biotech company advancing next-generation cell therapies using its proprietary TFome™ technology, through its FUKOKU -THE MUTUAL for Next 100 Fund L.P. (TMN100).

Co-founded by renowned geneticist George Church, GCTx is redefining the development of off-the-shelf cell therapies with applications across a wide array of therapeutic areas, including gastrointestinal, neurological, and immunological diseases. With a successful $65M Series A financing, GCTx is poised to revolutionize cell therapy by making these therapies more scalable and accessible to patients worldwide.

GCTx’s TFome™ platform is a leap forward in enabling cell therapies that overcome the limitations of current approaches, which often rely on complex, patient-specific manufacturing processes. The company’s cutting-edge approach unlocks the potential of iPSC-based therapies, which can significantly reduce the time and cost associated with cell reprogramming.

This investment underscores Global Brain's commitment to advancing cutting-edge biotechnology and improving patient outcomes globally. Global Brain is excited to be part of their journey to unlock new treatments that can address critical unmet medical needs.

About GCTx

Location
Massachusetts, US
Representatives
Parastoo Khoshakhlagh, CEO
Alex Ng, CTO
Founded
April 2019
URL
https://www.gc-tx.com/

About TMN100

Name
FUKOKU -THE MUTUAL for Next 100 Fund L.P.
General Partner
Global Brain Corporation

About Global Brain

Location
Tokyo, Japan
Representative
Yasuhiko Yurimoto
Founded
January 1998
URL
https://globalbrains.com/